Shareholders approve NeoGenomics (NASDAQ: NEO) equity plan amendment and board slate
NeoGenomics, Inc. (NASDAQ: NEO) stockholders approved a second amendment to the 2023 Equity Incentive Plan, increasing authorized shares by 5,000,000. All nine director nominees were elected, and stockholders also gave advisory approval for Named Executive Officer compensation and ratified Deloitte & Touche LLP as the independent registered public accountant. The annual meeting saw high participation with 89.61% of outstanding voting stock represented.
NeoGenomics stock (US64049M2098): Q1 update keeps focus on cancer testing demand
NeoGenomics (NGMS) reported Q1 2026 earnings with an EPS of $0.01, maintaining investor focus on the company's role in cancer diagnostics. The company's business model centers on cancer genetics diagnostic testing and pharma services, making its performance closely tied to oncology innovation and healthcare spending. Investors are advised to watch for continued testing demand, profitability improvements, and insights from upcoming investor conferences.
NEOGENOMICS (NEO) 13G/A: Greenhouse reports 9,215,903 shares (7.1%)
Greenhouse Funds LLLP, Greenhouse GP LLC, and Joseph Milano have filed an amended Schedule 13G/A for NEOGENOMICS (NEO), reporting beneficial ownership of 9,215,903 shares, which represents 7.1% of the common stock. This filing indicates a passive investment, with shares held by advisory clients of Greenhouse Funds LLLP. The document details shared voting power of 8,318,358 shares and shared dispositive power of all 9,215,903 shares.
NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics, Inc. announced its participation in two upcoming investor conferences: the 23rd Annual Craig-Hallum Institutional Investor Conference on May 28th, and the Jefferies Global Healthcare Conference 2026 on June 4th. The company will hold investor 1x1 meetings at both events, with a fireside chat scheduled for the Jefferies conference which will also be webcast. NeoGenomics is a leading provider of oncology diagnostic solutions.
Laser Focus World - NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics, Inc. (NASDAQ: NEO) announced its participation in two upcoming investor conferences: the 23rd Annual Craig-Hallum Institutional Investor Conference and the Jefferies Global Healthcare Conference 2026. The company, a leading provider of oncology diagnostic solutions, will hold investor 1x1 meetings at both events and a fireside chat at the Jefferies conference. A webcast of the Jefferies fireside chat will be available on their investor relations website.
Millennium group reports 2.22M NEO shares (1.7%) — Joint filing (NEO)
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended Schedule 13G/A report, disclosing shared voting and dispositive power over 2,222,757 shares of NeoGenomics (NEO) common stock, representing 1.7% of the class. This filing clarifies beneficial ownership through entities under their discretion and includes a Joint Filing Agreement dated May 12, 2026. Analysts consider this a routine passive ownership disclosure given the sub-5% holding and note the filing does not indicate any acquisition or sale transactions.
NeoGenomics (NEO) COO exercises RSUs, withholds shares for taxes and holds 164,032 shares
NeoGenomics Inc.'s President & Chief Operating Officer, Warren Stone, exercised 5,830 restricted stock units (RSUs) on May 11, 2026. Of these, 3,783 shares were withheld to cover tax obligations, resulting in him directly holding 164,032 shares of NeoGenomics common stock after the transactions. The filing also details his extensive equity compensation package, including various performance and restricted stock units, and stock options tied to vesting schedules and performance goals.
NeoGenomics (NEO) EVP adds shares via RSU vesting while covering taxes
NeoGenomics (NEO) EVP and General Counsel Alicia C. Olivo recently acquired 3,944 shares through the vesting of Restricted Stock Units (RSUs), while simultaneously having 2,559 shares withheld to cover tax obligations. Following this transaction, she directly holds 96,126 shares of common stock. The filing also details her extensive equity incentives, including various tranches of RSUs, Performance Stock Units (PSUs), and stock options with diverse exercise prices and expiration dates extending to 2036.
Is NeoGenomics’ Higher 2026 Revenue Outlook And Narrower Loss Profile Altering The Investment Case For NEO?
NeoGenomics, Inc. raised its full-year 2026 revenue guidance to US$797.0 million–US$803.0 million and reported a narrower net loss of US$17.11 million for Q1 2026. This improved outlook, driven by increasing test volumes and new assay launches, supports the company's investment narrative of growing oncology test adoption. However, investors still need to consider the risk of high fixed costs and ongoing investments potentially impacting profitability if revenue growth slows.
Is NeoGenomics’ Higher 2026 Revenue Outlook And Narrower Loss Profile Altering The Investment Case For NEO?
NeoGenomics recently revised its 2026 revenue guidance upwards and reported a narrower net loss for Q1 2026, driven by growing oncology test adoption. While these improvements suggest increasing traction for its cancer testing platform, the company remains loss-making, and investors should consider the ongoing risk posed by its high fixed costs and infrastructure investments against its revenue growth. The narrative projects significant revenue and earnings growth by 2029, suggesting a potential undervaluation.
NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of "Hold" by Brokerages
NeoGenomics, Inc. (NASDAQ:NEO) has received a "Hold" consensus recommendation from thirteen brokerages, with an average 1-year price target of $13.86. Despite matching EPS estimates and beating revenue expectations with an 11.3% year-over-year increase, the company continues to report negative margins and a negative return on equity. Shares were down 1.2% on Friday, trading below both its 200-day moving average and its 52-week high.
First Light, Mathew Arens report 10.8% stakes in Neogenomics (NEO)
First Light Asset Management, LLC and Mathew P. Arens have jointly filed an amended Schedule 13G/A, disclosing their beneficial ownership in Neogenomics, Inc. First Light now beneficially owns 13,631,016 shares, representing 10.47% of the class, while Mathew P. Arens beneficially owns 14,093,416 shares, or 10.82%. This filing indicates shared voting and dispositive power for both entities.
NEO SEC Filings - Neogenomics Inc 10-K, 10-Q, 8-K Forms
This page provides Neogenomics Inc. (NEO) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms, with AI-powered summaries. Recent filings detail board appointments, equity awards to directors, and financial results. The platform aims to offer transparency into the company's activities as a public cancer diagnostics business.
NeoGenomics (NEO) EVP updates equity awards, reports tax-withholding share move
NeoGenomics (NEO) EVP, GC & Business Development Alicia C. Olivo reported a disposition of 1,042 common shares on May 1, 2026, for tax withholding purposes. Following this transaction, she directly holds 92,182 common shares, in addition to a significant portfolio of restricted stock units, performance stock units, and stock options. The filing clarifies that this was a tax-related transaction and not an open-market sale, maintaining her substantial long-term incentive position in the company.
NeoGenomics (NEO) CAO exercises RSUs, surrenders shares for taxes
NeoGenomics Chief Accounting Officer Greg D. Aunan exercised 5,372 restricted stock units and surrendered 2,246 shares to cover tax obligations. After these transactions, he directly holds 25,153 shares of common stock. Aunan also retains various unexercised stock options and RSU awards with expiration dates extending to 2036.
NeoGenomics (NEO) COO exercises RSUs, shares withheld for tax
NeoGenomics, Inc.'s President & COO, Warren Stone, reported exercising 5,969 Restricted Stock Units (RSUs) on May 2, 2026. A portion of these shares, 2,349, were withheld by the company to cover tax obligations. Following these transactions, Stone directly holds 161,985 shares of common stock, in addition to significant stock options and performance stock units.
Liquidity Mapping Around (NEO) Price Events
This article analyzes Neogenomics Inc. (NEO) with a focus on liquidity mapping around price events, indicating strong sentiment across all time horizons. It highlights an exceptional risk-reward setup targeting a 28.7% gain and presents three distinct AI-generated trading strategies. The report details signal strength, support, and resistance levels for near-term, mid-term, and long-term traders.
NeoGenomics (NEO) Is Up 13.9% After Strong Q1 Revenue And New Epic Aura Integration
NeoGenomics (NEO) reported strong first-quarter 2026 results with increased sales and a reduced net loss. Concurrently, its oncology testing portfolio is now integrated with Epic Aura, making cancer diagnostics accessible through Epic's electronic health record workflows. This combination of improved financial performance and deeper integration into oncology practices is expected to influence NeoGenomics' long-term investment narrative by potentially boosting test adoption and volume.
NeoGenomics (NasdaqCM:NEO) Stock Forecast & Analyst Predictions
NeoGenomics (NEO) is projected to grow earnings by 57.4% and revenue by 8.5% annually, with EPS expected to increase by 56.6%. The company, though currently unprofitable, is undergoing strategic transitions from a diagnostic provider to a precision oncology platform, expanding its test offerings and receiving Medicare coverage for new technologies like PanTracer LBx and RaDaR ST. Analysts have revised price targets upwards, reflecting optimism about future growth, despite past stock volatility and ongoing net losses.
NeoGenomics Reports First Quarter 2026 Results, Increases Full-Year Revenue Guidance
NeoGenomics, Inc. announced strong first-quarter 2026 results, with total revenue increasing 11% year-over-year to $187 million, driven by a 14% growth in clinical revenue. The company also raised its full-year 2026 revenue guidance to a range of $797-$803 million, reflecting significant product launches including RaDaR® ST and PanTracer™ LBx, and improved financial performance with a decreased net loss and increased Adjusted EBITDA.
Vanguard holds 6.61M NeoGenomics shares (NEO) — 5.09% stake
Vanguard Capital Management reported a 5.09% passive stake in NeoGenomics Inc. (NEO), holding 6,610,272 shares of common stock. This disclosure was made in a Schedule 13G SEC filing, indicating Vanguard's investment intent is passive rather than aiming to influence company control. The filing specifies Vanguard's sole dispositive power over all shares and sole voting power over 954,449 shares.
NeoGenomics reports Q1 revenue increase
Fort Myers-based NeoGenomics Inc., a provider of oncology diagnostic solutions, announced a double-digit year-over-year revenue increase and a 34% reduction in net loss for the first quarter of 2026. Consolidated revenue reached $187 million, an 11% increase from the previous year, with average revenue per clinical test rising by 8%. CEO Tony Zook highlighted the quarter as transformational, emphasizing the company's progress in delivering advanced cancer testing.
Vanguard Portfolio Management holds 5.91% of NeoGenomics (NEO) common stock
Vanguard Portfolio Management has reported beneficial ownership of 7,677,794 shares of NeoGenomics Inc. (NEO), representing 5.91% of the outstanding common stock. This disclosure was made via a Schedule 13G SEC filing, indicating Vanguard holds significant dispositive power over these shares, with a smaller portion having sole voting power. The filing emphasizes the passive investment nature of this stake and includes several Vanguard affiliates in the reporting group.
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2026 Earnings Call Transcript
NeoGenomics, Inc. reported strong first-quarter 2026 results, exceeding revenue and earnings expectations with 11% year-over-year revenue growth to $186.7 million and a 27% increase in Adjusted EBITDA. The company saw robust clinical revenue growth of 14%, primarily driven by its Next-Generation Sequencing (NGS) business, which grew 26% and now constitutes one-third of clinical revenue. NeoGenomics raised its full-year 2026 revenue guidance, citing earlier-than-expected MolDX approval for PanTracer Liquid and continued strong performance across its portfolio, particularly in community oncology settings and new product launches like RaDaR ST.
Leerink Upgrades NeoGenomics to Outperform From Market Perform, Adjusts Price Target to $25 From $12
Leerink has upgraded NeoGenomics (NEO) from Market Perform to Outperform and increased its price target from $12 to $25. This adjustment follows NeoGenomics' recent financial report, which included Q1 2026 adjusted EPS of $0.01 per share and revenue of $186.7 million, both meeting or exceeding FactSet estimates. The company also projects full-year 2026 revenue between $797 million and $803 million.
NeoGenomics stock surges following earnings, two upgrades
NeoGenomics Inc. shares surged over 7% after Leerink analysts upgraded the stock to Outperform from Market Perform, increasing their price target to $25. The upgrade followed the cancer diagnostics company's strong first-quarter 2026 financial results, which reported $187 million in revenue, exceeding analyst expectations, and a 27% increase in adjusted EBITDA. Benchmark analysts also upgraded the stock to Buy, citing solid performance.
NeoGenomics Reports First Quarter 2026 Results
NeoGenomics, Inc. reported an 11% year-over-year increase in total revenue to $187 million for the first quarter of 2026, driven by a 14% growth in clinical revenue. The company also announced an increase in its full-year 2026 revenue guidance to a range of $797-$803 million. Key operational highlights include the launch of the RaDaR® ST ctDNA assay for molecular residual disease (MRD) and favorable MolDX coverage for its PanTracer™ LBx blood-based genomic profiling test, initiatives aimed at expanding its precision medicine offerings in oncology.
Earnings Flash (NEO) NeoGenomics, Inc. Posts Q1 Adjusted EPS $0.01 per Share, vs. FactSet Est of $0.01
NeoGenomics, Inc. (NEO) reported its Q1 adjusted EPS at $0.01 per share, matching FactSet's estimate. The company also announced full-year 2026 revenue expectations of $797 million to $803 million, slightly above FactSet's estimate of $796.7 million. These results were published on April 28, 2026.
NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c
NeoGenomics (NEO) reported first-quarter adjusted EPS of 1c, surpassing the consensus estimate of 0c, and revenue of $187M, exceeding the $184.48M consensus. CEO Tony Zook highlighted the quarter's transformation with double-digit revenue growth and significant advancements in cancer testing, including the launch of the RaDaR ST MRD assay and MolDX reimbursement coverage for PanTracer LBx. These innovations are expected to drive long-term revenue growth and improve patient outcomes.
NeoGenomics (NEO) Q1 2026 Earnings Transcript
NeoGenomics reported strong Q1 2026 results with an 11% year-over-year revenue increase, surpassing guidance, and raised full-year revenue outlook to $797 million-$803 million. The company's clinical revenue grew 14%, driven by a 26% surge in Next-Generation Sequencing (NGS) revenue, now comprising a third of clinical revenue. Key growth drivers included the launch of RADAR ST for MRD and MolDX approval for PanTracer Liquid, alongside strategic investments in sales and operational efficiency.
NeoGenomics: Q1 Earnings Snapshot
NeoGenomics Inc. (NEO) reported a Q1 loss of $17.1 million, or 13 cents per share, which adjusted to 1 cent per share, surpassing Wall Street expectations. The cancer-focused testing laboratory operator also exceeded revenue forecasts with $186.7 million and projects full-year revenue of $797 million to $803 million.
NeoGenomics (NASDAQ: NEO) grows Q1 revenue and raises 2026 outlook
NeoGenomics (NASDAQ: NEO) reported robust financial results for Q1 2026, with revenue increasing 11% year-over-year to a record $187 million, driven by strong clinical revenue growth and improved average revenue per test. The company narrowed its net loss and saw a significant rise in Adjusted EBITDA, prompting an upward revision of its full-year 2026 revenue guidance to between $797 million and $803 million. NeoGenomics also expanded its oncology testing portfolio with the launch of RaDaR ST MRD assay and expanded PanTracer offerings.
[10-Q] NEOGENOMICS INC Quarterly Earnings Report
NeoGenomics Inc. (NEO) filed its quarterly earnings report (10-Q) for the period ended March 31, 2026, showing a net loss of $17.106 million (basic and diluted net loss per share of $0.13) compared to a net loss of $25.923 million ($0.20 per share) in the prior year. Revenue increased by 11.1% to $186.672 million, driven by higher test volumes and a shift to higher-value tests, partially offset by lower non-clinical revenue. The report also details the company's financial condition, including assets, liabilities, cash flows, and key accounting policies, while outlining strategic focus areas for 2026.
NeoGenomics Reports First Quarter 2026 Results
NeoGenomics, Inc. announced its first-quarter 2026 results, reporting an 11% year-over-year increase in total revenue to $187 million, driven by a 14% growth in Clinical revenue. The company also raised its full-year 2026 revenue guidance to a range of $797-$803 million. Key operational highlights included the launch of the RaDaR® ST ctDNA assay and a favorable MolDX coverage decision for PanTracer™ LBx, further strengthening its oncology diagnostic solutions portfolio.
NeoGenomics sees Q4 revenue of about $190M
NeoGenomics announced its preliminary fourth-quarter revenue, expecting it to be approximately $190 million. This figure indicates the company's financial performance at the close of the last fiscal quarter.
How NeoGenomics’ Epic Aura Integration Could Reshape Test Adoption For NEO Investors
NeoGenomics announced the integration of its oncology testing portfolio into Epic Aura, allowing oncologists to order and view test results directly within the Epic electronic health record system. This integration could significantly ease adoption barriers for hospitals, potentially boosting test volumes and accelerating the adoption of newer, higher-value assays like liquid biopsy and molecular residual disease testing. While this development strengthens NeoGenomics' investment narrative by connecting clinical access and reimbursement with existing EHR systems, investors are still cautioned about risks such as high fixed costs and intense competition.
NeoGenomics Investor Alert
Faruqi & Faruqi, LLP is investigating potential claims against NeoGenomics, Inc. (NASDAQ: NEO) and encourages investors who lost over $100,000 to seek lead plaintiff status by February 6, 2023. The investigation concerns alleged false and misleading statements made by NeoGenomics, leading to a dramatic decline in stock value.
Why NeoGenomics (NEO) Stock Is Trading Up Today
NeoGenomics (NEO) stock rose 4.1% after announcing the integration of its oncology testing portfolio with the Epic Aura platform, a major electronic health record system. This integration aims to simplify test ordering and results viewing for physicians, potentially increasing test adoption by 20-30% per site. Despite today's positive movement, the stock has been volatile, dropping significantly over the last year due to disappointing earnings and trading well below its 52-week high.
NeoGenomics Expands Oncology Testing Access With Epic Aura EHR Integration
NeoGenomics has integrated its full oncology testing portfolio with Epic Aura, allowing physicians and health systems nationwide to order diagnostic tests and review results directly within their existing EHR workflows. This integration aims to reduce administrative friction, accelerate decision-making for cancer treatment, and potentially increase test adoption by 20% to 30% per site. The move enhances NeoGenomics' digital health strategy by streamlining access to advanced diagnostic offerings like liquid biopsy and molecular residual disease testing.
NeoGenomics integrates testing portfolio with Epic Aura EHR
NeoGenomics Inc. announced the integration of its oncology testing portfolio with Epic Aura, allowing physicians to order tests and view results directly within the Epic electronic health record system. This integration aims to improve access to NeoGenomics' tests for solid tumors and hematologic malignancies, potentially increasing test adoption by 20-30%. Despite a 30% year-to-date decline in shares, the company, with $727 million in revenue, is projected to become profitable this year with expected earnings of $0.15 per share.
Cancer doctors can order NeoGenomics tests inside Epic records
NeoGenomics has integrated its oncology testing portfolio into Epic Aura, allowing seamless access for oncologists and health systems across the U.S. This integration enables physicians to order comprehensive cancer tests and view results directly within the Epic electronic health record (EHR) system. The company anticipates this streamlined process will accelerate clinical decisions, drive a 20-30% increase in test adoption, and support faster treatment times for cancer patients.
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
NeoGenomics, Inc. announced its oncology testing portfolio is now available through Epic Aura, an integration designed to streamline access for oncologists and health systems. This aims to simplify the ordering of comprehensive tests for solid tumors and hematologic malignancies, view results within the Epic EHR system, and potentially increase test adoption by 20-30% per site. The integration is expected to accelerate clinical decisions and drive scalable precision oncology adoption, reducing barriers for healthcare providers and getting patients on appropriate therapies sooner.
NEO Financials: Income Statement, Balance Sheet & Cash Flow | Neogenomics Inc
This article provides a detailed financial overview of Neogenomics Inc (NEO) based on its FY2025 SEC filings, including income statements, balance sheets, and cash flow data. Despite improved revenue growth and a strong balance sheet with low leverage and high liquidity, the company reported significant accounting losses and negative free cash flow. The analysis highlights that while the business is moving towards self-funding, it still needs more scale to absorb overhead and achieve profitability.
NeoGenomics (NEO) Projected to Post Earnings on Tuesday
NeoGenomics (NASDAQ:NEO) is expected to announce its Q1 2026 earnings before market open on Tuesday, April 28th, with analysts projecting $0.0060 EPS and $184.53 million in revenue. The company had previously beaten estimates in its last report, though it reported negative net margin and return on equity. Shares are currently trading at $8.23, holding a "Hold" consensus rating from analysts with an average price target of $11.86.
NeoGenomics Inc stock (US64049M2098): Why does its oncology testing model matter more now?
NeoGenomics Inc specializes in oncology testing, an increasingly vital field as precision medicine gains traction. The company's vertically integrated lab network, broad test menu, and dual revenue streams from clinical and pharma services position it for resilient growth. Investors looking for exposure to the booming U.S. and English-speaking oncology diagnostics markets may find NeoGenomics an attractive option due to its specialized focus and potential for long-term expansion despite existing risks.
NeoGenomics (NEO) Meets Q2 Earnings Estimates
This article reports that NeoGenomics (NEO) met its Q2 earnings estimates. The company reported adjusted earnings of $0.01 per share, aligning with the Zacks Consensus Estimate, though this figure represents a year-over-year decline. Revenues for the quarter came in at $137 million, surpassing expectations.
NeoGenomics (NEO) Meets Q2 Earnings Estimates
This article provides details on NeoGenomics' (NEO) Q2 earnings, highlighting that the company met earnings estimates. It presents key financial figures including GAAP EPS, revenue, and year-over-year changes, alongside the company's stock performance relative to the industry and S&P 500.
NeoGenomics, Inc. Experiences Evaluation Revision Amidst Market Performance Challenges
NeoGenomics, Inc. experienced a stock price adjustment, closing at $8.16, and has significantly underperformed the S&P 500 over the past year with a -14.64% return. The stock has shown considerable volatility, with a 52-week high of $13.74 and a low of $4.72. Technical indicators suggest mixed to bearish trends, highlighting ongoing challenges for the small-cap biotechnology company.
NeoGenomics (NASDAQ:NEO) Stock Price Down 5.3% - Here's What Happened
NeoGenomics (NASDAQ:NEO) shares fell 5.3% on Thursday, closing at $8.2170 with a trading volume significantly below average. The company reported a Q4 EPS of $0.06 and revenue of $190.17 million, exceeding analyst estimates, but still operates with negative net margins. Analyst ratings are mixed, with a consensus "Hold" and an average target price of $11.86, despite some recent target increases.
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
NeoGenomics (NASDAQ: NEO) announced it will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego, Calif., from April 17–22, 2026. The presentations will highlight how combining laboratory testing with clinical data can support oncology research and drive AI-based analysis to generate clinically relevant insights for therapy development. This showcases NeoGenomics' capabilities in characterizing biomarker prevalence and bridging translational research with clinical application.
